[Expert consensus on immunotherapy-based combination conversion therapy followed by sequential surgery for advanced hepatocellular carcinoma(2026 edition)].

Authors

Hepatobiliary and Pancreatic Disease Prevention and Control Committee of the Chinese Preventive Medicine Association, Liver Cancer Committee of the Chinese Anti-Cancer Association, Hepatic Surgery Group of the Surgical Branch of the Beijing Medical Association, Hepatic Oncology Committee, China International Exchange and Promotive Association for Medical and Health Care

Published in

Zhonghua wai ke za zhi [Chinese journal of surgery]. Volume 64. Issue 11. Pages 1142-1156. Sep 21, 2026. Epub Sep 21, 2026.

Abstract

Patients diagnosed with hepatocellular carcinoma (HCC) are often already at an advanced stage at the time of initial diagnosis, with limited effective curative treatment options available and a generally poor overall prognosis. In recent years, combination therapy regimens incorporating immune checkpoint inhibitors have demonstrated clinical advantages in improving the objective response rate and prolonging patient survival. Following standardized transition therapy, some patients with initially unresectable advanced HCC may subsequently undergo curative hepatectomy or liver transplantation, ultimately achieving stable long-term survival benefits. To further standardize the comprehensive management of the sequential surgical treatment approach in the immunotherapy-based transition therapy for advanced HCC, relevant academic organizations have convened multidisciplinary experts to revise and update the content of this consensus, drawing upon the latest evidence-based data since the publication of the "Expert consensus on the sequential surgery following conversion therapy based on the combination of immune checkpoint inhibitors and antiangiogenic targeted drugs for advanced hepatocellular carcinoma（2024 edition）" and incorporating domestic clinical practice experience. This initiative aims to guide clinicians in making informed diagnostic and therapeutic decisions, maximize patient treatment benefits, and contribute to the continuous advancement of comprehensive HCC management standards in China.

PMID:
42765409
Bibliographic data and abstract were imported from PubMed on 21 Sep 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.